Cardiol Historical Balance Sheet
CRDL Stock | USD 1.33 0.03 2.21% |
Trend analysis of Cardiol Therapeutics Class balance sheet accounts such as Short Long Term Debt Total of 133.9 K, Other Current Liabilities of 622.2 K or Total Current Liabilities of 5.5 M provides information on Cardiol Therapeutics' total assets, liabilities, and equity, which is the actual value of Cardiol Therapeutics to its prevalent stockholders. By breaking down trends over time using Cardiol Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Cardiol Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cardiol Therapeutics is a good buy for the upcoming year.
Cardiol Therapeutics Inventory |
|
Cardiol |
About Cardiol Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Cardiol Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Cardiol Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cardiol Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cardiol currently owns. An asset can also be divided into two categories, current and non-current.
Cardiol Therapeutics Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Cardiol Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cardiol Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Cardiol Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cardiol Therapeutics Class are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most accounts from Cardiol Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Cardiol Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. At this time, Cardiol Therapeutics' Total Current Assets are quite stable compared to the past year. Intangible Assets is expected to rise to about 371 K this year, although the value of Other Current Liabilities will most likely fall to about 622.2 K.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 117.6K | 72.9K | 174.3K | 133.9K | Total Assets | 87.9M | 62.0M | 36.7M | 38.6M |
Cardiol Therapeutics balance sheet Correlations
Click cells to compare fundamentals
Cardiol Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cardiol Therapeutics balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 15.5M | 15.9M | 87.9M | 62.0M | 36.7M | 38.6M | |
Short Long Term Debt Total | 190.8K | 156.6K | 117.6K | 72.9K | 174.3K | 133.9K | |
Other Current Liab | 640.1K | 696.1K | 7.4M | 1.4M | 655.0K | 622.2K | |
Total Current Liabilities | 690.5K | 2.5M | 11.6M | 9.8M | 8.3M | 5.5M | |
Total Stockholder Equity | 14.7M | 13.3M | 76.2M | 52.2M | 28.2M | 33.0M | |
Net Tangible Assets | 14.1M | 12.8M | 75.9M | 51.9M | 59.7M | 32.7M | |
Property Plant And Equipment Net | 584.0K | 479.6K | 356.5K | 295.7K | 337.1K | 329.6K | |
Net Debt | (6.8M) | (13.9M) | (83.8M) | (59.4M) | (34.8M) | (36.5M) | |
Retained Earnings | (31.2M) | (51.9M) | (83.5M) | (114.4M) | (142.6M) | (135.4M) | |
Accounts Payable | 561.3K | 1.8M | 4.1M | 8.3M | 7.6M | 3.9M | |
Cash | 7.0M | 14.0M | 83.9M | 59.5M | 34.9M | 34.3M | |
Non Current Assets Total | 1.1M | 943.2K | 735.7K | 590.5K | 547.4K | 610.6K | |
Cash And Short Term Investments | 7.0M | 14.0M | 83.9M | 59.5M | 34.9M | 34.3M | |
Net Receivables | 927.9K | 219.9K | 407.1K | 480.2K | 279.9K | 452.2K | |
Common Stock Shares Outstanding | 25.8M | 29.9M | 43.2M | 62.5M | 64.5M | 41.5M | |
Liabilities And Stockholders Equity | 15.5M | 15.9M | 87.9M | 62.0M | 36.7M | 38.6M | |
Non Current Liabilities Total | 140.3K | 104.7K | 72.9K | 22.4K | 158.5K | 109.5K | |
Other Stockholder Equity | 4.8M | 8.8M | 12.7M | 15.6M | 18.8M | 10.0M | |
Total Liab | 830.8K | 2.6M | 11.6M | 9.8M | 8.5M | 5.7M | |
Net Invested Capital | 14.7M | 13.3M | 76.2M | 52.2M | 60.0M | 33.4M | |
Total Current Assets | 14.4M | 14.9M | 87.1M | 61.4M | 36.2M | 37.8M | |
Net Working Capital | 13.7M | 12.4M | 75.6M | 51.6M | 59.4M | 32.5M | |
Intangible Assets | 548.1K | 463.7K | 379.2K | 294.8K | 210.4K | 371.0K | |
Common Stock | 39.4M | 51.9M | 142.9M | 147.5M | 148.5M | 89.8M | |
Property Plant Equipment | 584.0K | 479.6K | 356.5K | 295.7K | 340.1K | 322.7K | |
Inventory | 1.1M | 18.0K | 339.1K | (279.9K) | (251.9K) | (239.3K) | |
Other Current Assets | 5.4M | 347.8K | 2.8M | 1.5M | 1.2M | 1.6M | |
Capital Stock | 39.4M | 51.9M | 142.9M | 147.5M | 169.7M | 92.1M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.38) | Return On Assets (0.54) | Return On Equity (1.08) |
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.